Coulter Corporation

Paulette E Smariga

Stephan D Glenn

Kenneth H Kortright

David E Hofheinz

Edward O'Connell

Song Y Lee

Meryl A Forman

Gregory Butchko

Candie S Stoner

David M Allman

A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove up to about 98% of the endotoxins in addition to removing viruses with an efficiency of at least 4.6.times.10.sup.5 and DNA to less than 10 picograms per 500 mg sample.

Process and apparatus for removal of DNA, viruses and endotoxins

A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6.times.10.sup.5 ; remove DNA from levels of 10 .mu.g/sample to levels below 10 picograms per 500 mg sample of monoclonal antibody; and will remove at least 97% of some bacterial endotoxins.

Process and apparatus for removal of DNA and viruses

A solid-phase immunoassay is provided for determination of HIV antigens in human physiological fluid. The immunoassay is characterized by the coating of a solid substrate with a unique monoclonal antibody which recognizes a common antigenic determinant of a group of HIV core antigens and no HIV envelope antigens of HIV. The test sample preferably also is subjected to a lysing reagent prior to the incubation for uniformly dispersing antigens which may be present in the test sample.

Enzyme immunoassay for detecting HIV antigens in human sera

A solid-phase immunoassay is provided for determination of members of an immunological pair such as antigen and/or antibody of a single binding pair in human physiological fluid, wherein a single immunoassay enables simultaneous detection of antigen and/or antibody of a single binding pair in a test sample which may have circulating antigen and/or antibody. The immunoassay is characterized by the addition of an amount of antigen or 'spike' of the binding pair to the test sample prior to incubation of the test sample in the presence of a solid-phase absorbed antibody of the binding pair. The test sample preferably also is subjected to a lysing reagent prior to the incubation for uniformly dispensing antigens which may be present in the test sample.

Growing community of inventors

N. Miami, FL, United States of America

Paulette E Smariga